Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.

Adv Ther · 2021 · PMC8475485 · PMID 34564806

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The confirmatory phase 3 KEYNOTE-604 trial, however, did not reach statistical significance for the primary endpoint of OS, leading to voluntary withdrawal by the manufacturer of the US SCLC indication for pembrolizumab in March 2021 [ 31 , 72 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.